Pepsin synergist and application thereof
The bases isolated from the fermentation supernatant of Bacillus subtilis X13 significantly enhance pepsin activity, solve the problem of improving pepsin activity in the prior art, and achieve safe and efficient improvement of digestive function. It is suitable for food and medicine, with a wide range of Application prospects.
Patent Information
- Application Number
- CN202411318509.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-20
- Publication Date
- 2024-11-08
- Estimated Expiration
- 2044-09-20
AI Technical Summary
The prior art is difficult to effectively improve the activity of pepsin, resulting in functional indigestion and related gastrointestinal diseases. There are already safety risks for pepsin synergists, such as the potential toxicity of Cu2+ and Li+ to the body.
The bases such as cytosine, uracil, guanine and adenine were isolated from the fermentation supernatant of Bacillus subtilis X13, and the activity of pepsin was significantly enhanced through a specific concentration of base solutions, and a pepsin synergist was developed. In food and medicine, it includes oral liquid, chewable tablets, soft capsules, etc.
Significantly improve the catalytic efficiency of pepsin, improve digestive function, enhance the digestive utilization rate of protein, improve the nutritional quality and breeding efficiency of food, and due to the use of natural bases, the market prospects are good.
Smart Images

Figure CN118903143A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of promoting digestion, and in particular relates to a pepsin enhancer and application thereof. Background Art
[0002] Functional dyspepsia is very common, and most people have experienced it. The cause of the disease is mainly related to mental and psychological factors. It often occurs in elderly patients, which has a great adverse effect on the quality of life of patients. Human digestion mainly depends on digestive enzymes secreted by the gastrointestinal tract. Western medicine generally supplements digestive enzymes to relieve the symptoms of dyspepsia. Pepsin in gastric juice breaks down protein in food into smaller peptides and peptones. It is the most important digestive enzyme in gastric juice and plays an indispensable role in the digestion of protein foods. In addition, existing studies have shown that pepsin plays an important role in peptic ulcers, gastric cancer, aspiration pneumonia, gastroesophageal reflux disease and related diseases caused by reflux such as reflux esophagitis, chronic rhinosinusitis, otitis media and other diseases. Traditional Chinese medicine mainly treats dyspepsia by strengthening the spleen and stomach. Chinese patent medicines such as Baohe Pills are often used to treat dyspepsia. Their digestive and stagnation-relieving and food accumulation syndrome treatment functions are related to their ability to significantly increase the activity of pepsin. Increasing the activity of pepsin can effectively improve patients' abdominal discomfort, early satiety, nausea and vomiting, abdominal distension and other symptoms, thereby achieving the therapeutic goal of improving patients' decreased digestive function.
[0003] The present invention separates active strain Bacillus subtilis X13 from persimmon enzyme, and the fermentation supernatant (centrifugation condition 10000rpm, 5min) after high temperature inactivation (20min at 100℃) can significantly enhance the activity of pepsin, thereby improving the catalytic efficiency of pepsin. After separation, purification and identification analysis of the fermentation supernatant, the inventor found that cytosine, uracil and guanine in the fermentation supernatant all have the effect of improving the activity of pepsin. Further research shows that the other two base molecules (thymine and adenine) existing in nature also have pepsin synergistic effects to varying degrees, and the synergistic effect of uracil is the most significant among the five bases. So far, there is no research report on the effect of bases on enhancing the activity of pepsin at home and abroad.
[0004] The invention has a wide range of application scenarios. For example, by adding pepsin enhancers to food, the digestion and utilization rate of protein by the human body can be improved to improve the nutritional quality of food, thereby enhancing human health. In addition, it can also be used to produce animal feed that improves breeding efficiency, which can assist endogenous pepsin activity and improve the digestion and absorption rate of protein by animals, thereby promoting animal growth. Base is an endogenous molecule in humans and animals, and is safe for organisms. Therefore, the invention has a good development prospect and is of great significance for the development of digestive foods, health foods and animal feed additives. Summary of the invention
[0005] The present invention first discovered a strain of Bacillus subtilis, which was separated from a high-sugar persimmon enzyme stock solution prepared in the laboratory. The fermentation broth of the strain has the effect of enhancing the activity of pepsin. The inventor conducted in-depth research on the fermentation broth and found that the alkaline solution at a specific concentration has the effect of enhancing the activity of pepsin, and applied it in medicines and foods, specifically including the following contents.
[0006] First, the present invention provides a pepsin enhancer, which comprises at least one of cytosine, uracil, guanine, thymine and adenine.
[0007] Wherein, the synergistic dosage of cytosine, uracil and adenine is 0.036-0.054 mmol / L.
[0008] Wherein, the synergistic dosage of guanine and thymine is 0.022-0.045 mmol / L.
[0009] Second, the present invention provides a pepsin enhancing oral liquid, which is an aqueous solution of five bases, wherein the five bases are cytosine, uracil, guanine, thymine and adenine.
[0010] Wherein, the concentration of the alkaline aqueous solution is 50-300 mg / L.
[0011] The pepsin enhancing oral liquid also contains flavoring agents and preservatives.
[0012] The flavoring agents are sucrose, monosyrup, fructose syrup, orange peel syrup, citron syrup, cherry syrup, licorice syrup, cinnamon syrup, steviol glycoside, sorbitol, mannitol, citric acid, tartaric acid and vitamin C, and the preservative is potassium sorbate.
[0013] Wherein, the content of the flavor corrective is 30-80 g / L, and the content of the preservative is 10-80 mg / L.
[0014] Finally, based on the above-mentioned mechanism of enhancing the activity of pepsin, the present invention also provides a chewable tablet, soft capsule, capsule or tablet for promoting digestion, wherein the chewable tablet, soft capsule, capsule or tablet contains five base powders, wherein the five bases are cytosine, uracil, guanine, thymine and adenine, wherein the content of cytosine, uracil and adenine is 1 to 50 mg, and the content of guanine and thymine is 1 to 30 mg.
[0015] The chewable tablet also contains compressible starch, microcrystalline cellulose and skimmed milk powder.
[0016] Beneficial Effects
[0017] Pepsin is essential for the absorption and utilization of protein by the human body. For gastrointestinal digestive dysfunction and the various chronic gastrointestinal diseases caused by it, supplementing pepsin can have a positive impact on digestion and absorption and auxiliary treatment in compensating for the lack, decline or loss of the body's digestive function. It has the advantages of strong specificity, low required dosage and significant efficacy. Therefore, the development of pepsin series products is of great significance to the nutrition and food fields. The use of pepsin as a digestive aid and dietary supplement has been quite common in the West for decades, but the research on natural pepsin enhancers at home and abroad is still blank.
[0018] The uracil studied in the present invention can effectively increase the biochemical reaction rate of pepsin as a pepsin enhancer. It can be made into a mixed dietary supplement with pepsin to help improve the gastrointestinal motility of patients, facilitate digestion and nutrient absorption, and improve the therapeutic effect of functional dyspepsia. In addition, uracil is a natural base and is harmless to humans and animals. 2+ , Li + Trace metal ions such as Cu ions pose certain safety risks to the body. 2+ It has a damaging effect on cell membranes, proteins and nucleic acids. It directly binds to the acylated components in the TCA cycle, causing oligomerization of acylated proteins and loss of iron-sulfur cluster proteins, inducing protein toxicity stress and ultimately leading to cell death. + In terms of the application of lithium salts, the most serious adverse cardiovascular reaction is sinus node dysfunction, which is one of the manifestations of cardiac toxicity. Therefore, when using lithium salts, special attention should be paid to factors that may aggravate lithium toxicity or lithium accumulation. These are all factors that may cause the use of Cu 2+ , Li + Potential safety risks of trace metal ions such as pepsin enhancers.
[0019] In addition, currently available pepsin supplements are all derived from animals, while the pepsin enhancer studied by the present invention can improve the pepsin activity of the human or animal body itself, which will undoubtedly greatly increase the safety and effectiveness of its application. The pepsin enhancer of the present invention is a natural base, acid-resistant and high-temperature-resistant, and the activity of pepsin after being treated with the pepsin activator of the present invention is increased by 1.48 times. The method for activating pepsin of the present invention is simple, particularly suitable for preparing health products and medicines that help digestion, with low cost and good market prospects. BRIEF DESCRIPTION OF THE DRAWINGS
[0020] Figure 1 This is the silica gel chromatography elution curve of Bacillus subtilis X13 pepsin enhancer.
[0021] Figure 2This is the elution curve of the macroporous resin D-101 column chromatography of fraction 6.
[0022] Figure 3 This is the 500-190nm wavelength spectrum scan of fraction 4 sample solution. DETAILED DESCRIPTION
[0023] The present invention is described in detail below with reference to examples. All methods and techniques are conventional methods and techniques.
[0024] In the present invention, pepsin (30000U / g), tyrosine (purity 99%), hemoglobin, cytosine (purity 99%), uracil (purity 98%), thymine (purity 99%), guanine (purity 98%), and adenine (purity 98%) are from Shanghai Yuanye Biotechnology Co., Ltd.; trichloroacetic acid (AR) is from Shanghai McLean Biochemical Technology Co., Ltd.; methanol (AR), petroleum ether (AR), and ethyl acetate (AR) are from Chengdu Cologne Chemical Co., Ltd.; acetone (AR) is from Wuxi Zhanwang Chemical Reagent Co., Ltd.; silica gel (100-200 meshes) is from Shanghai Haohong Biomedical Technology Co., Ltd.; and macroporous resin D-101 is from Anhui Samsung Resin Co., Ltd.
[0025] The method for measuring pepsin activity in the present invention is as follows.
[0026] 1. Preparation method of control solution and test solution.
[0027] (1) Acid solution: Take 65 mL of 1 mol / l hydrochloric acid, add pure water to 1000 mL, mix well and set aside.
[0028] (2) Hemoglobin test solution: Weigh 1 g of bovine hemoglobin, add acid solution to dissolve it to 100 mL, mix well and set aside.
[0029] (3) 5% trichloroacetic acid solution: Weigh 5 g of trichloroacetic acid, add pure water to 100 mL, mix well and set aside.
[0030] (4) Tyrosine control solution: Weigh 14.5 mg of tyrosine dried to constant weight at 105°C, add acid solution to 100 mL, mix well and set aside.
[0031] (5) Pepsin test solution: Weigh 0.01 g of pepsin, add 12 mL of acid solution, and mix to obtain a 25 U / mL pepsin solution. Dilute the pepsin solution to 0.25 U / mL with acid solution to obtain a pepsin test solution.
[0032] (6) Test solution: Mix 2 mL of the inactivated and cooled fermentation supernatant with 2 mL of the pepsin test solution, and react in a water bath at 37°C for 5 min to obtain the test solution experimental group. Mix 2 mL of the acid solution with 2 mL of the pepsin test solution, and react in a water bath at 37°C for 5 min to obtain the test solution control group.
[0033] 2. Method for determining pepsin activity.
[0034] Determination of the pepsin experimental group: Take 1 test tube in the experimental group, add 5mL of hemoglobin test solution and keep it in a 37℃ water bath, add 1mL of the test sample solution experimental group or control group, shake well and keep it in a 37℃ water bath for 10 minutes, add 5mL of 5% trichloroacetic acid immediately after completion, shake well, filter with three layers of filter paper, and take the filtrate for use. Take another test tube as the blank group, add 5mL of hemoglobin, keep it in a 37℃ water bath for 10 minutes, add 5mL of 5% trichloroacetic acid immediately after completion, shake well, add 1mL of the test solution, filter with three layers of filter paper, and take the filtrate for use. Use a spectrophotometer to zero the blank group at a wavelength of 275nm and determine the absorbance of the filtrate of the experimental group as A.
[0035] Determination of tyrosine control group: Take 1 test tube (do three parallels), add 1mL of tyrosine control solution, keep it in a 37℃ water bath for 5min, then add 5mL of hemoglobin test solution that has been preheated to 37℃, shake well and keep it in a 37℃ water bath for 10min, immediately add 5mL of 5% trichloroacetic acid solution, shake well, leave it at room temperature for 5min, filter it with slow qualitative filter paper, and take the filtrate for use. Take another test tube as the blank group, add 5mL of hemoglobin test solution, keep it at 37℃ for 10min, immediately add 5mL of 5% trichloroacetic acid solution, shake well and add 1mL of acid solution. Use a spectrophotometer to zero the blank group at a wavelength of 275nm and determine the absorbance of the tyrosine control group filtrate as A'.
[0036] The calculation formula of pepsin activity is as follows: incubate at 37°C for 10 min, and 1 pepsin activity unit (U) is defined as the amount of 1 μmol of tyrosine produced by catalysis of substrate per minute.
[0037]
[0038] Where A: absorbance of pepsin experimental group; A': absorbance of tyrosine control group; W: sample weight, g; W S : The amount of tyrosine in each 1mL of reference solution, μg; n: The dilution multiple of the test sample
[0039] 3. Method for determining the activity of pepsin enhancer.
[0040] Pepsin enhancer activity (times / mL) = 2×(pepsin activity of the test sample experimental group / pepsin activity of the test sample control group - 1)
[0041] Example 1
[0042] The applicant found that the high-sugar persimmon enzyme stock solution has a significant function of aiding digestion, so the effective strains therein were studied. The results showed that Bacillus subtilis X13 in one of the persimmon enzyme stock solutions has the function of high-yield pepsin activator.
[0043] The methods for extraction, separation, purification and identification of the active ingredients of pepsin enhancer in the fermentation supernatant of Bacillus subtilis X13 are as follows.
[0044] (1) Methanol removal: The fermentation supernatant was subjected to rotary evaporation (20 r / min, 40°C) and concentrated 10 times. An equal volume of methanol was added to the concentrate, and the mixture was placed in a 4°C refrigerator after shaking. After standing for 1 hour, the mixture was centrifuged (10000 r / min, 10 min, 4°C). After centrifugation, the supernatant was taken and rotary evaporated (20 r / min, 40°C) to remove methanol. The concentrate was transferred to a separatory funnel and used for extraction.
[0045] (2) Petroleum ether extraction: Take an equal volume of petroleum ether to the concentrate after methanol treatment and add it to a separatory funnel. Shake it thoroughly. After standing and stratifying, separate the lower layer of concentrate and the upper layer of organic phase and place them in a beaker. Repeat the extraction of the concentrate for 5 times. Combine and collect the separated organic phases in a beaker. After the extraction is completed, the organic phase is subjected to rotary evaporation (20r / min, 40°C) to remove the petroleum ether.
[0046] (3) Silica gel column chromatography: Weigh 30 g of silica gel (100-200 mesh) and place it in a beaker. Add 50 mL of a mixture of petroleum ether and ethyl acetate in a volume ratio of 9:1. Stir well and pour into the chromatography column. After filling, use a rubber-tipped dropper to evenly drop the sample solution extracted with petroleum ether on the surface of the silica gel bed. Elute with an eluent in a volume ratio of petroleum ether and ethyl acetate in a volume ratio of 9:1. The elution rate is 5 mL / min. The amount of eluent is 600 mL. 50 mL is one fraction. The obtained fraction 6 is rotary evaporated to dryness (20 r / min, 40°C) and then re-dissolved with 5 mL of pure water for later use.
[0047] (4) Macroporous resin column chromatography: Weigh 50g of macroporous resin D-101 and soak it in anhydrous ethanol for at least 24h, wash it repeatedly with ultrapure water until it is free of ethanol, and set aside. Weigh the pretreated macroporous resin, add 100mL of the sample solution extracted with petroleum ether (the concentration is 7.5 times the concentration of the original solution), stir evenly and place it in an oscillating incubator (120r / min, 20℃, 2h) to allow the enzyme enhancer to be fully adsorbed in the macroporous resin. After the adsorption is completed, load the macroporous resin D-101 onto the column, and the column loading volume is 1 / 2 of the volume of the chromatography column. During the process, the chromatography column is constantly tapped with an ear bulb. After the column loading is completed, drop the fraction 6 sample solution evenly on the surface of the macroporous resin bed. Elute with 500mL of acetone. There is no need to collect the fraction in this process. Then continue to elute with 200mL of acetone, 20mL per fraction, and the obtained fraction 4 is rotary evaporated to dryness (20r / min, 40℃) and re-dissolved with 2mL of pure water for later use.
[0048] Identification method of active ingredients of pepsin enhancer
[0049] (1) Metabolite extraction: Pipette 50 μl of the sample fraction 4 prepared in 1.2.3.2 into an EP tube, add 200 μl of extraction solution (methanol:acetonitrile = 1:1 (V / V)), the extraction solution contains an isotope-labeled internal standard; vortex mix for 30 seconds, sonicate for 10 minutes (ice-water bath); let stand at -40°C for 1 hour; centrifuge the sample at 4°C, 12,000 rpm for 15 minutes; take the supernatant and put it in a sample injection bottle for detection.
[0050] (2) On-machine detection: Vanquish (Thermo Fisher Scientific) ultra-high performance liquid chromatograph was used to separate the target compounds by chromatography on a Waters ACQUITY UPLC BEH Amide (2.1 mm × 50 mm, 1.7 μm) liquid chromatography column. Phase A of the liquid chromatography was an aqueous phase containing 25 mmol / L ammonium acetate and 25 mmol / L ammonia water, and phase B was acetonitrile. Sample plate temperature: 4 °C, injection volume: 2 μl. The Orbitrap Exploris 120 mass spectrometer was able to perform primary and secondary mass spectrometry data acquisition under the control of the control software (Xcalibur, version: 4.4, Thermo). The detailed parameters are as follows: Sheath gas flow rate: 50Arb, Aux gas flow rate: 15Arb, Capillary temperature: 320℃, Full ms resolution: 60000, MS / MS resolution: 15000, Collision energy: SNCE 20 / 30 / 40, Spray Voltage: 3.8kV (positive) or -3.4kV (negative).
[0051] (3) Data processing: The raw data were converted into mzXML format using ProteoWizard software, and metabolite identification was performed using a collaboratively written R package, using the BiotreeDB (V3.0)7 database, and then visual analysis was performed using an independently written R package.
[0052] The fermentation supernatant of Bacillus subtilis X13 was purified by methanol, extracted by petroleum ether, and chromatographed by silica gel column to collect fraction 6 ( Figure 1 ), and then fraction 6 was chromatographed on a macroporous resin D101 column to collect fraction 4 ( Figure 2 ), 500-190nm wavelength spectrum scanning spectrum ( Figure 3 ) It can be seen that the sample of fraction 4 has absorption peaks at 194nm and 265nm in the ultraviolet spectrum. Fraction 4 was sent to liquid-mass spectrometry, and a total of 208 level 1 organic substances were identified, that is, the metabolites in the sample matched the MS1, MS2 and RT of the standard. Based on the chemical properties of the pepsin enhancer produced by strain X13, that is, weak polarity and absorption peaks at 194nm and 265nm in the ultraviolet spectrum, the inventors screened out cytosine, uracil and guanine as possible targets and conducted the following verification experiments.
[0053] Example 2
[0054] This example verifies the synergistic effect of five bases on pepsin, and the specific method is as follows: a certain amount of cytosine, uracil, thymine, guanine, and adenine are weighed respectively, and according to the concentration in the previous fermentation broth and preliminary experiments, the five bases are respectively prepared to a concentration of 0.022, 0.036, 0.045, and 0.054 mmol / L using sterilized and cooled YEPD liquid culture medium, and the fermentation supernatant is replaced to prepare the sample solution to be tested, and the rest of the method is the same.
[0055] The experiment showed that the solubility of the five bases in the sterilized liquid culture medium was significantly higher than that in pure water, and the sterilized liquid culture medium had no pepsin synergist effect, which would not interfere with the determination of the synergistic effect of the bases. Therefore, the subsequent experiments used the sterilized liquid culture medium to dissolve the bases. The experiment found that higher concentrations of cytosine, uracil and guanine solutions had no pepsin synergistic effect, but when diluted to a certain extent, they would show a certain pepsin synergistic effect, among which uracil had the most significant synergistic effect. As shown in Table 1, 0.045mmol / L uracil solution can increase pepsin by 1.48 times. This experiment further measured the remaining two natural bases (thymine and adenine). These two natural bases also showed a similar trend, that is, they showed pepsin synergist activity only at lower concentrations, but their synergistic activity was lower than that of uracil.
[0056] Since pepsin activity is also affected by substrate concentration, that is, when the synergist increases the catalytic efficiency of pepsin, but the enzyme substrate concentration is not enough to support high-efficiency enzyme catalysis, the synergistic effect of the synergist may be affected. Therefore, this experiment studied the effect of increasing hemoglobin concentration on the synergistic effect of uracil. The results showed that when the hemoglobin concentration increased by 0.5, 1, and 1.5 times, the synergistic activity of 0.045mmol / L uracil was 1.12, 1.19, and 1.28 times that of the control group (hemoglobin concentration remained unchanged), respectively. Moreover, as shown in Table 1, under the three concentration gradients measured, the synergistic activity of 0.054mmol / L uracil solution was significantly lower than that of 0.045mmol / L. However, when the substrate concentration increased by 1.5 times, the synergistic activity of 0.054mmol / L and 0.066mmol / L uracil solutions were 1.034 and 1.046 times that of 0.045mmol / L uracil solution, respectively, indicating that the decrease in the synergistic activity of uracil when the concentration increased was due to insufficient substrate concentration. Therefore, when eating, the substrate concentration of pepsin will increase, and the synergistic effect of uracil will also increase, and the phenomenon of decreased synergistic effect of higher concentration uracil will not occur.
[0057] Table 1 The synergistic activity of five base solutions at different concentrations on pepsin
[0058]
[0059] Example 3
[0060] The inventors further determined whether there is a synergistic effect between the three bases with higher synergistic activity (cytosine, uracil, and thymine). The results are shown in Table 2. The results show that whether it is a combination of two (1:1) or a combination of three (1:1:1), the synergistic activity of the combination liquid is lower than the sum of the synergistic activities of each monomer, especially the combination of uracil + thymine, whose synergistic activity is 65% lower than the sum of the activities of uracil and thymine. Therefore, whether there is a synergistic effect between cytosine, uracil, and thymine, using uracil alone is the best choice.
[0061] Table 2 The synergistic activity of the combination of three bases on pepsin
[0062]
[0063] Example 4
[0064] In this example, in order to explore whether the length of contact time between uracil and pepsin in the stomach will affect its synergistic effect when uracil is used as a pepsin synergist in actual application, the experimental results are shown in Table 3. The synergistic activity of uracil is the highest when it is in contact with pepsin for 5 minutes, but when the contact time is shorter, its synergistic activity is also higher. For example, after only contacting with pepsin for 1 minute, uracil has a synergistic activity of 1.05 times, indicating that its onset time is faster. Therefore, uracil is more practical as a pepsin synergist.
[0065] Table 3 Effect of contact time of uracil and pepsin on synergistic effect
[0066]
[0067] Example 5
[0068] This embodiment provides several oral liquids for improving the activity of pepsin, which are cytosine oral liquid, uracil oral liquid, guanine oral liquid, thymine oral liquid and adenine oral liquid.
[0069] The cytosine oral solution includes cytosine, sucrose and potassium sorbate. The specific preparation method is: accurately weigh 250 mg of cytosine and 50 g of sucrose and dissolve them in 1 L of deionized water to prepare a sucrose solution with a final concentration of 250 mg / L cytosine, and then add 50 mg of potassium sorbate thereto to obtain a cytosine oral solution with improved pepsin activity.
[0070] The uracil oral solution includes uracil, sucrose and potassium sorbate. The specific preparation method is: accurately weigh 255 mg of uracil and 50 g of sucrose and dissolve them in 1 L of deionized water to prepare a sucrose solution with a final concentration of 255 mg / L uracil, and then add 50 mg of potassium sorbate thereto to obtain a uracil oral solution with improved pepsin activity.
[0071] The guanine oral solution includes guanine, sucrose and potassium sorbate. The specific preparation method is: accurately weigh 270 mg of guanine and 50 g of sucrose and dissolve them in 1 L of deionized water to prepare a sucrose solution with a final concentration of 270 mg / L guanine, and then add 50 mg of potassium sorbate thereto to obtain a guanine oral solution that improves the activity of pepsin.
[0072] The thymine oral solution includes thymine, sucrose and potassium sorbate. The specific preparation method is: accurately weigh 225 mg of thymine and 50 g of sucrose and dissolve them in 1 L of deionized water to prepare a sucrose solution with a final concentration of 225 mg / L thymine, and then add 50 mg of potassium sorbate thereto to obtain a thymine oral solution with improved pepsin activity.
[0073] The adenine oral solution includes adenine, sucrose and potassium sorbate. The specific preparation method is: accurately weigh 300 mg of adenine and 50 g of sucrose and dissolve them in 1 L of deionized water to prepare a sucrose solution with a final concentration of 300 mg / L adenine, and then add 50 mg of potassium sorbate thereto to obtain an adenine oral solution that improves the activity of pepsin.
[0074] The cytosine oral solution includes cytosine, sucrose and potassium sorbate. The specific preparation method is: accurately weigh 150 mg of cytosine and 30 g of sucrose and dissolve them in 1 L of deionized water to prepare a sucrose solution with a final concentration of 150 mg / L cytosine, and then add 20 mg of potassium sorbate thereto to obtain a cytosine oral solution with improved pepsin activity.
[0075] The uracil oral solution includes uracil, sucrose and potassium sorbate. The specific preparation method is: accurately weigh 100 mg of uracil and 80 g of sucrose and dissolve them in 1 L of deionized water to prepare a sucrose solution with a final concentration of 100 mg / L uracil, and then add 30 mg of potassium sorbate thereto to obtain a uracil oral solution with improved pepsin activity.
[0076] The guanine oral solution includes guanine, sucrose and potassium sorbate. The specific preparation method is: accurately weigh 50 mg of guanine and 60 g of sucrose and dissolve them in 1 L of deionized water to prepare a sucrose solution with a final concentration of 50 mg / L guanine, and then add 80 mg of potassium sorbate thereto to obtain a guanine oral solution that improves the activity of pepsin.
[0077] The thymine oral solution includes thymine, sucrose and potassium sorbate. The specific preparation method is: accurately weigh 120 mg of thymine and 60 g of sucrose and dissolve them in 1 L of deionized water to prepare a sucrose solution with a final concentration of 120 mg / L thymine, and then add 40 mg of potassium sorbate thereto to obtain a thymine oral solution that improves the activity of pepsin.
[0078] The adenine oral solution includes adenine, sucrose and potassium sorbate. The specific preparation method is: accurately weigh 180 mg of adenine and 30 g of sucrose and dissolve them in 1 L of deionized water to prepare a sucrose solution with a final concentration of 180 mg / L adenine, and then add 10 mg of potassium sorbate thereto to obtain an adenine oral solution that improves the activity of pepsin.
[0079] Preliminary animal experiments have shown that the activity of pepsin in mice can be increased by 0.5 to 1.2 times after 1 mL of the base oral solution prepared by the above method is administered intragastrically.
[0080] Sucrose is added as a flavoring agent. Sucrose can be replaced by monosyrup, fructose syrup, orange peel syrup, citron syrup, cherry syrup, licorice syrup and cinnamon syrup. At the same time, stevioside, sorbitol and mannitol can also be used as flavoring agents. In order to improve the taste, citric acid, tartaric acid and vitamin C can be added in an amount of 1 to 10 g / L.
[0081] Example 6
[0082] A method for preparing a digestion-aiding alkaline chewable tablet, wherein the main ingredients of the tablet include compressible starch, microcrystalline cellulose, skimmed milk powder and five kinds of alkaline powders, and the tablet is prepared by tablet pressing. In this embodiment, the formula of a tablet is as follows.
[0083] Table 4: Formula of base chewable tablets
[0084]
[0085] Similarly, since the above embodiments have proved that the core active ingredient of the present invention is a single base, namely cytosine, uracil, guanine, thymine and adenine, other dosage forms, such as soft capsules, capsules containing 1 to 5 mg of cytosine, uracil or adenine, or 1 to 3 mg of guanine or thymine, can achieve the effect of improving the activity of pepsin.
[0086] Example 7
[0087] A drug for promoting animal digestion, in the form of soft capsules or capsules, containing 1-50 mg of cytosine, uracil or adenine or 1-30 mg of guanine or thymine, the dosage of which is determined according to the gastric acid amount of the animal and the average water content of a meal, and can increase the activity of animal pepsin after addition, thereby achieving the effect of helping animal digestion. According to preliminary animal experiments, the activity of mouse pepsin can be increased by 0.5-1.3 times.
Claims
1. Pepsin enhancer, Features: The pepsin enhancer comprises at least one of cytosine, uracil, guanine, thymine and adenine.
2. The pepsin enhancer according to claim 1, Features: The synergistic dosage of cytosine, uracil and adenine is 0.036-0.054 mmol / L; the synergistic dosage of guanine and thymine is 0.022-0.045 mmol / L.
3. A pepsin enhancing oral solution, Features: The pepsin enhancing oral solution is an aqueous solution of five bases, wherein the five bases are cytosine, uracil, guanine, thymine and adenine.
4. The pepsin enhancing oral solution according to claim 3, Features: The concentration of the alkaline aqueous solution is 50-300 mg / L.
5. The pepsin enhancing oral solution according to claim 3, Features: The pepsin synergistic oral liquid also contains flavor correctives and preservatives.
6. The pepsin enhancing oral solution according to claim 5, Features: The flavoring agents are sucrose, monosaccharide syrup, fructose syrup, orange peel syrup, citron syrup, cherry syrup, licorice syrup, cinnamon syrup, steviol glycoside, sorbitol, mannitol, citric acid, tartaric acid and vitamin C, and the preservative is potassium sorbate.
7. The pepsin enhancing oral solution according to claim 5, Features: The content of the flavoring agent is 30-80 g / L, and the content of the preservative is 10-80 mg / L.
8. A chewable tablet, soft gelatin capsule, capsule or tablet for promoting digestion, suitable for humans or animals, Features: The chewable tablet, soft capsule, capsule or tablet contains five base powders, and the five bases are cytosine, uracil, guanine, thymine and adenine.
9. The chewable tablet, soft capsule, capsule or tablet for promoting digestion according to claim 8, Features: The content of cytosine, uracil and adenine is 1-50 mg, and the content of guanine and thymine is 1-30 mg.
10. Application of a five-base solution, wherein the five bases are cytosine, uracil, guanine, thymine and adenine, It is characterized in that An aqueous solution of cytosine, uracil and adenine with a concentration of 0.036-0.054 mmol / L and an aqueous solution of guanine and thymine with a concentration of 0.022-0.045 mmol / L are used to increase the activity of pepsin.
Citation Information
Patent Citations
Application of five normal basic groups of human body in preparation of medicines for treating tumors
CN102406649A
Pepsin intensifier, pepsin composition and application of pepsin intensifier
CN102660529A
Application of river deer milk in preparation of medicines or health-caring products for promoting digestion
CN106236775A
Application of nucleoside analogue in preparation of medicine for preventing or treating gastrointestinal diseases
CN114533739A
Manufacture of Preparations of Pepsin containing Hydrochloric Acid.
GB190512526A
